Sildenafil
WHO Grade III Glioma
Virginia Commonwealth UniversitySmall moleculePhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 41/ 100
- Competitive Position
- 89/ 100
Competitive context
23 Active assets in the WHO Grade III Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Virginia Commonwealth University | Phase 2 | BB |
Everolimus Nationwide Children's Hospital | Phase 2 | B |
Fycompa Mayo Clinic | Phase 4 | B |
Lomustine M.D. Anderson Cancer Center | Phase 2 | B |
THIOGUANINE ANHYDROUS M.D. Anderson Cancer Center | Phase 2 | B |
View all 38 →
Same molecule, other indications
Sildenafil is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →